REPLY
15.5.2024 14:01:32 CEST | Business Wire | Press release
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot and will showcase its transformative potential at the Milan 2024 Xchange event on May 15-16 through a live immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515336953/en/
Reply, with its company WM Reply, has collaborated with Microsoft to fully harness and promote the capabilities of Microsoft 365 Copilot. As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. (Graphic: Business Wire)
As a partner in Microsoft’s Early Access Program (EAP), Reply has leveraged its extensive experience and insights to assist organisations in achieving early successes with Copilot. This collaboration aims to tailor Copilot solutions to specific business needs, from automating routine tasks and enhancing data security to accelerating app development and improving collaboration. A tailored roadmap, developed in collaboration with Microsoft, guides organisations through the implementation and maximisation of Copilot’s capabilities.
Understanding the importance of adoption, Reply has developed a five-step approach to ensure that the benefits of Copilot M365 are accessible to a wide corporate audience. This approach aligns with Microsoft AI Lab’s vision and focuses on integrating Copilot into daily operations effectively. The below Copilot maturity model framework aims to help customers assess their current state and their desired state with Copilot, and to identify the gaps and the actions needed to achieve their goals:
- Approach – Exploring the art of the possible, technical readiness and align with company strategy.
- Assess – Plan a pilot where we take the early-adopters on a journey with measurement qualitative and quantitative. Use those results to create a business case and roll-out plan.
- Adopt – Set-up a CoE for Copilot. Land key messages and provide training using a scenario/functional specific approach.
- Embed – Make Copilot Business as Usual at or your organisation. Manage a dynamic licensing approach and stay on top of new features.
- Extend – Bring the power of copilot to wider application.
Immersive Introduction at Milan Xchange
Held annually, Reply’s Xchange brings together technology leaders and innovators to explore the latest in digital solutions and strategies. This year, Reply will debut the “AI-Scape Room," an immersive virtual escape room experience developed by WM Reply and powered by Microsoft Copilot for Microsoft 365. This demonstration will highlight how Copilot enhances productivity, security, and collaboration within business processes through advanced AI integration.
The AI-Scape Room is designed to foster teamwork and communication as participants collaborate to solve puzzles and challenges with the assistance of Copilot’s AI-driven insights. The bespoke escape room is an opportunity for all participants to experience, explore and discover how to utilise M365 copilot as the hands-on challenges provide valuable insights into the potential of AI in enhancing workplace efficiency and engagement.
For more information on Reply’s M365 Copilot Adoption approach, the AI-Scape Room and Reply's AI-based solutions, visit: www.reply.com
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
WM REPLY
WM Reply is the Reply Group company specialising in improving employees day-to-day lives through modern workplace solutions and connecting consumers to products and experiences they love online. We support our clients from beginning to end; designing and building their solution and easing adoption. Making sure our clients are not just enjoying the benefits of the cloud but exploiting them as well. We are recognised as leaders within Sitecore, Dynamics 365, Office 365 and the products within such as SharePoint, Power Platform, Yammer and Microsoft Teams. A Microsoft Gold Partner five times over! We have a colourful team who are famous for their imagination, delivery, passion for technology and most importantly, their pride in delivery. www.wm.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515336953/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom